Evidence map›Paper›PMID 40093664›Full record

ArticleWorld journal of gastroenterology2025

Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment.

Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang, Fu-Shan Tang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. [Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hai-Nan MaDepartment of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Kai-Sen CaoDepartment of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Yan-Miao LiuDepartment of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Cheng ChenDepartment of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Hang ZhangDepartment of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Fu-Shan TangDepartment of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that demonstrates a promising safety and efficacy profile. A recent study by Peng

Indexed as

AdenineAntiviral AgentsHepatitis B, ChronicHepatitis B virusTenofovirAlanineAlanine TransaminaseHumansProdrugsTreatment OutcomeAdenineAlanineAlanine TransaminaseAntiviral AgentsProdrugsTenofovirtenofovir alafenamideAntiviral efficacyChronic hepatitis BHyperlipidemiaSafety profileTenofovir alafenamideTenofovir amibufenamide

Identifiers

PMID40093664
PMCPMC11886539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.